株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

新興する南アフリカの医薬品市場:医薬品登録プロセスの加速へ向けた新医薬品規制当局(SAHPRA)導入の提案

Emerging Pharmaceutical Market in South Africa - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process

発行 GBI Research 商品コード 244536
出版日 ページ情報 英文 74 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GBI Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
新興する南アフリカの医薬品市場:医薬品登録プロセスの加速へ向けた新医薬品規制当局(SAHPRA)導入の提案 Emerging Pharmaceutical Market in South Africa - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process
出版日: 2012年06月12日 ページ情報: 英文 74 Pages
概要

南アフリカにおける医薬品市場額は、2011年の38億米ドルから今後CAGR9.2%で拡大し、2018年に70億米ドルに達すると予測されています。

当レポートでは、南アフリカの医薬品市場における動向および課題について詳細に分析し、全体的な医薬品・アウトソーシング市場構造の分析、主要企業の競合ベンチマーキング、M&A・戦略的提携の分析を提供しており、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 新興する南アフリカの医薬品市場:産業の特徴

  • 南アフリカの医薬品市場規模・成長率
  • 公害病の負担
  • 特許薬・ジェネリック医薬品の市場シェア
  • 輸出入
  • 南アフリカの主な国内企業
  • 南アフリカの主な外国企業
  • 市場促進因子・阻害因子
  • PESTLE分析

第4章 新興する南アフリカの医薬品市場:マクロ経済環境

  • 人口統計の分析
  • GDP
  • 医療費
  • 医療制度

第5章 新興する南アフリカの医薬品市場:医療規制

  • 南アフリカにおける医薬品規制
  • 知的財産権
  • 健康保険の適用範囲
  • 価格・医療費償還
  • 臨床試験

第6章 新興する南アフリカの医薬品市場:産業動向

  • 戦略的検討事項
  • M&A
  • ライセンシング合意

第7章 新興する南アフリカの医薬品市場:委託研究機関産業

  • 委託研究機関
  • 南アフリカにおける主な国際的委託研究機関
  • 南アフリカにおける主な国内の委託研究機関

第8章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GBIHC204MR

Summary

GBI Research's new report, "Emerging Pharmaceutical Market in South Africa - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process" provides in-depth analysis of the trends, issues and challenges in South Africa's pharmaceutical market. The report analyzes the overall pharmaceutical and outsourcing market structure, and provides competitive benchmarking for leading companies. It also analyzes the M&A and strategic partnerships that are shaping the pharmaceutical market. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.

South Africa's pharmaceutical market is one of the most attractive markets in Africa. Some of the main reasons for its rapid growth are the availability of cost-effective and skilled labor, high quality infrastructure, and the introduction of the South African Health Products Regulatory Authority (SAHPRA). Most of the local drug manufacturers and distributors are in the hands of big international pharmaceutical firms. GBI Research valued the South African pharmaceutical market at $3.8 billion in 2011, and expects it to reach $7 billion in 2018 at a Compound Annual Growth Rate (CAGR) of 9.2%. South Africa's healthcare sector is set to witness a number of new healthcare reform plans in the future, with the primary objective being to reduce the growing drug expenditure by increasing the use of generics. The healthcare system aims to cover the entire population under the National Health Insurance (NHI) scheme, which it will start implementing in a small population of 10 districts by 2012.

GBI Research's analysis shows that generics accounted for over 60% of the volume of the pharmaceutical market in 2011. Government reforms have encouraged the manufacture and use of generic drugs as a tool to limit drug expenditure and provide low-cost effective public healthcare. The combination of government healthcare policies and numerous active generic manufacturing companies points to an increased generic market share in the forecast period.

Scope

  • Overall pharmaceutical and outsourcing market structure in South Africa
  • Market characterization, including market size, major regulatory bodies, pricing and reimbursement issues, major distribution channels, and intellectual property rights
  • Contract Research Organization (CRO) market growth
  • Analysis of the leading segments within the South African pharmaceutical industry
  • Key drivers and restraints impacting the market
  • Competitive benchmarking of leading companies in the pharmaceutical and CRO markets in South Africa
  • Key M&A activities and strategic partnership deals that took place between 2009 and mid-2011

Reasons to buy

  • Develop market-entry and market expansion strategies by identifying the leading emerging markets poised for strong growth
  • Devise a more tailored country strategy through the understanding of key drivers of and barriers to South Africa's pharmaceutical market
  • Develop key strategic initiatives by understanding the key focus areas of leading companies
  • Accelerate and strengthen your market position by identifying key companies for M&A and strategic partnerships

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

3. Emerging Pharmaceutical Market: South Africa - Industry Characteristics

  • 3.1. Pharmaceutical Market Size and Growth in South Africa
  • 3.2. Environmental Disease Burden
    • 3.2.1. HIV/AIDS
    • 3.2.2. Tuberculosis
  • 3.3. Patented and Generic Drugs Market Share
  • 3.4. Imports and Exports
    • 3.4.1. Imports
    • 3.4.2. Exports
    • 3.4.3. Balance of Trade
  • 3.5. Key Domestic Players in South Africa
    • 3.5.1. Aspen Pharmacare
    • 3.5.2. Adcock Ingram
    • 3.5.3. Cipla Medpro
  • 3.6. Key Foreign Players in South Africa
    • 3.6.1. Sanofi
    • 3.6.2. Pfizer
    • 3.6.3. Roche
    • 3.6.4. Ranbaxy
    • 3.6.5. GlaxoSmithKline
    • 3.6.6. Merck & Co
    • 3.6.7. Novartis
  • 3.7. Market Drivers and Restraints
    • 3.7.1. Drivers
    • 3.7.2. Restraints
  • 3.8. PESTLE Analysis

4. Emerging Pharmaceutical Market: South Africa - Macroeconomic Environment

  • 4.1. Demographic Analysis
    • 4.1.1. Introduction
    • 4.1.2. Population Size, Growth and Structure
    • 4.1.3. Changes in Life Expectancy at Birth
    • 4.1.4. Infant Mortality Rate
    • 4.1.5. Rural/Urban Distribution
    • 4.1.6. Population by Gender
  • 4.2. Gross Domestic Product
  • 4.3. Healthcare Expenditure
  • 4.4. Healthcare System
    • 4.4.1. Health Workforce and Infrastructure in South Africa

5. Emerging Pharmaceutical Market: South Africa - Healthcare Regulation

  • 5.1. Pharmaceutical Regulation in South Africa
  • 5.2. Intellectual Property Rights
  • 5.3. Health Insurance Coverage
  • 5.4. Pricing and Reimbursement
    • 5.4.1. Pricing
    • 5.4.2. Reimbursement
  • 5.5. Clinical Trials

6. Emerging Pharmaceutical Market: South Africa - Industry Trends

  • 6.1. Strategic Consolidations
  • 6.2. Mergers and Acquisitions
    • 6.2.1. Deals by Year
    • 6.2.2. Deals by Type
    • 6.2.3. Deals by Value
    • 6.2.4. Top M&A Deals
  • 6.3. Licensing Agreements
    • 6.3.1. Top Licensing Deals

7. Emerging Pharmaceutical Market: South Africa - Contract Research Organization Industry

  • 7.1. Contract Research Organizations
  • 7.2. Key International Contract Research Organization Players in South Africa
    • 7.2.1. Quintiles
    • 7.2.2. Pharmaceutical Product Development
    • 7.2.3. Inc Research
    • 7.2.4. Parexel
    • 7.2.5. Icon plc.
    • 7.2.6. PRA International
  • 7.3. Key Domestic Contract Research Organization Players in South Africa
    • 7.3.1. African Clinical Research Organization
    • 7.3.2. OnQ

8. Emerging Pharmaceutical Market: South Africa - Appendix

  • 8.1. Market Definitions
  • 8.2. Abbreviations
  • 8.3. Sources
  • 8.4. Research Methodology
    • 8.4.1. Industry Performance
    • 8.4.2. Macroeconomic Environment
    • 8.4.3. Healthcare Regulations
    • 8.4.4. Industry Trends
  • 8.5. Contact Us
  • 8.6. Disclaimer

List of Tables

  • Table 1: Emerging Pharmaceutical Market: South Africa, Market Forecast, 2007-2018
  • Table 2: Emerging Pharmaceutical Market: South Africa, Causes of Death, 2008
  • Table 3: Emerging Pharmaceutical Market: South Africa, Causes of Death due to Infectious Diseases, 2008
  • Table 4: Emerging Pharmaceutical Market: South Africa, HIV/AIDS Population (million), (%), 2001-2011
  • Table 5: Emerging Pharmaceutical Market: South Africa, Tuberculosis Population, 2001-2011
  • Table 6: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Imports, 2007-2018
  • Table 7: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Exports, 2007-2018
  • Table 8: Revised Timelines for Drug Approval Process by South African Health Products Regulatory Authority
  • Table 9: Emerging Pharmaceutical Market: South Africa, Population Structure in South Africa, (million), 2000-2025
  • Table 10: Emerging Pharmaceutical Market: South Africa, Population Parameters, 2009
  • Table 11: Emerging Pharmaceutical Market: South Africa, BRICS, Rural/Urban Distribution of Population, 2011
  • Table 12: Emerging Pharmaceutical Market: South Africa, Population by Gender(%), 1990-2025
  • Table 13: Emerging Pharmaceutical Market: South Africa, Macroeconomic Indicators, 2010 and 2015
  • Table 14: Emerging Pharmaceutical Market: South Africa, National Healthcare Coverage and Expenditure, 2007
  • Table 15: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Physicians, 2010
  • Table 16: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Nursing and Midwifery Personnel, 2010
  • Table 17: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Dentistry Personnel, 2010
  • Table 18: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Pharmaceutical Personnel, 2010
  • Table 19: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Hospital Beds per 10,000 Population, 2009
  • Table 20: Emerging Pharmaceutical Market: South Africa, Medicines Control Council Registration Fees for New Medicines, South Africa
  • Table 21: Emerging Pharmaceutical Market: South Africa, Revised Timelines for Drug Approval Process by South African Health Products Regulatory Authority, South Africa
  • Table 22: Emerging Pharmaceutical Market: South Africa, Government Employees Medical Scheme, South Africa
  • Table 23: Emerging Pharmaceutical Market: South Africa, Tiered Pricing System, 2010
  • Table 24: Emerging Pharmaceutical Market: South Africa, Number of Clinical Trials, 2007-2011
  • Table 25: Emerging Pharmaceutical Market: South Africa, Strategic Consolidations, Deals by Year, 2009-2011
  • Table 26: Emerging Pharmaceutical Market: South Africa, Recent M&A Deals, 2009-2011
  • Table 27: Emerging Pharmaceutical Market: South Africa, Recent Licensing Agreements, 2009-2011

List of Figures

  • Figure 1: Emerging Pharmaceutical Market: South Africa, Market Forecast, 2007-2018
  • Figure 2: Emerging Pharmaceutical Market: South Africa, Top 10 Causes of Death (%), 2008
  • Figure 3: Emerging Pharmaceutical Market: South Africa, Causes of Death due to Infectious Diseases (%), 2008
  • Figure 4: Emerging Pharmaceutical Market: South Africa, HIV/AIDS Population (million), 2001-2011
  • Figure 5: Emerging Pharmaceutical Market: South Africa, Deaths due to AIDS, 2001-2011
  • Figure 6: Emerging Pharmaceutical Market: South Africa, Transmission of HIV/AIDS, (%), 2011
  • Figure 7: Emerging Pharmaceutical Market: South Africa, Tuberculosis Population, 2001-2011
  • Figure 8: Emerging Pharmaceutical Market: South Africa, Patented vs. Generic Drugs, by Value, 2011
  • Figure 9: Emerging Pharmaceutical Market: South Africa, Patented vs. Generic Drugs Market Share %, by Volume, 2011
  • Figure 10: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Imports, 2007-2018
  • Figure 11: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Exports, 2007-2018
  • Figure 12: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Exports and Imports, 2007-2018
  • Figure 13: Emerging Pharmaceutical Market: South Africa, Aspen Pharmacare, SWOT Analysis, 2011
  • Figure 14: Emerging Pharmaceutical Market: South Africa, Adcock Ingram, SWOT Analysis, 2011
  • Figure 15: Emerging Pharmaceutical Market: South Africa, Cipla Medpro, SWOT Analysis, 2011
  • Figure 16: Emerging Pharmaceutical Market: South Africa, Sanofi, SWOT Analysis, 2011
  • Figure 17: Emerging Pharmaceutical Market: South Africa, Pfizer, SWOT Analysis, 2011
  • Figure 18: Emerging Pharmaceutical Market: South Africa, Roche, SWOT Analysis, 2011
  • Figure 19: Emerging Pharmaceutical Market: South Africa, Ranbaxy, SWOT Analysis, 2011
  • Figure 20: Emerging Pharmaceutical Market: South Africa, GlaxoSmithKline, SWOT Analysis, 2011
  • Figure 21: Emerging Pharmaceutical Market: South Africa, Merck and Co., SWOT Analysis, 2011
  • Figure 22: Emerging Pharmaceutical Market: South Africa, Novartis, SWOT Analysis, 2011
  • Figure 23: Emerging Pharmaceutical Market: South Africa, Market Drivers, 2011
  • Figure 24: Emerging Pharmaceutical Market: South Africa, Market Restraints, 2011
  • Figure 25: Emerging Pharmaceutical Market: South Africa, PESTLE Analysis, 2011
  • Figure 26: Emerging Pharmaceutical Market: South Africa, Population of BRICS Nations, 2010
  • Figure 27: Emerging Pharmaceutical Market: South Africa, Population Structure, (million), 2000-2025
  • Figure 28: Emerging Pharmaceutical Market: South Africa, Life Expectancy at Birth, 1950-2010
  • Figure 29: Emerging Pharmaceutical Market: South Africa, Infant Mortality Rate, 2001-2011
  • Figure 30: Emerging Pharmaceutical Market: South Africa, Rural/Urban Distribution of Population, 1990-2009
  • Figure 31: Emerging Pharmaceutical Market: South Africa, National Healthcare Expenditure, 2008
  • Figure 32: Emerging Pharmaceutical Market: South Africa, Private Healthcare Expenditure (%), 2010
  • Figure 33: Emerging Pharmaceutical Market: South Africa, Increase in Government Healthcare Expenditure over the Previous Year (%), 2011
  • Figure 34: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Physicians per 10,000 Population, 2010
  • Figure 35: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Nursing and Midwifery Personnel per 10,000 Population, 2010
  • Figure 36: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Dentistry Personnel per 10,000 Population, 2010
  • Figure 37: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Pharmaceutical Personnel per 10,000 Population, 2010
  • Figure 38: Emerging Pharmaceutical Market: South Africa, BRICS, Number of Hospital Beds per 10,000 Population, 2009
  • Figure 39: Emerging Pharmaceutical Market: South Africa, Number of Clinical Trials, 2007-2011
  • Figure 40: Emerging Pharmaceutical Market: South Africa, Strategic Consolidation, Deals by Type, (%), 2009-2011
  • Figure 41: Emerging Pharmaceutical Market: South Africa, Strategic Consolidations, Deals by Year, 2009-2011
  • Figure 42: Emerging Pharmaceutical Market: South Africa, M&A Deals by Year, 2009-2011
  • Figure 43: Emerging Pharmaceutical Market: South Africa, M&A Deals by Type, (%), 2009-2011
  • Figure 44: Emerging Pharmaceutical Market: South Africa, M&A Deals by Value, %, 2009-2011
  • Figure 45: Emerging Pharmaceutical Market: South Africa, Quintiles, Company Profile, 2011
  • Figure 46: Emerging Pharmaceutical Market: South Africa, Pharmaceutical Product Development, Company Profile, 2011
  • Figure 47: Emerging Pharmaceutical Market: South Africa, Inc Research, Company Profile, 2011
  • Figure 48: Emerging Pharmaceutical Market: South Africa, Parexel, Company Profile, 2011
  • Figure 49: Emerging Pharmaceutical Market: South Africa, Icon plc, Company Profile, 2011
  • Figure 50: Emerging Pharmaceutical Market: South Africa, PRA International, Company Profile, 2011
  • Figure 51: Emerging Pharmaceutical Market: South Africa, African Clinical Research Organization, Company Profile, 2011
  • Figure 52: Emerging Pharmaceutical Market: South Africa, OnQ, Company Profile, 2011
Back to Top